CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice.
about
The chemopreventive effects of Protandim: modulation of p53 mitochondrial translocation and apoptosis during skin carcinogenesisTargeting Oncogenic Mutant p53 for Cancer TherapyTumor suppressor p53 and its gain-of-function mutants in cancerTargeted rescue of a destabilized mutant of p53 by an in silico screened drugTargeting p53 for Novel Anticancer Therapy.Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells.Determination and stability of CP-31398 in plasma from experimental animals by LC-MS/MS.Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis.A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers.Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma.Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells.Pathogenesis of nonmelanoma skin cancers in organ transplant recipientsProcarcinogenic effects of cyclosporine A are mediated through the activation of TAK1/TAB1 signaling pathwayCurcuminoids activate p38 MAP kinases and promote UVB-dependent signalling in keratinocytesCyclosporine a mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epithelial-mesenchymal transition: role of TGFβ signaling pathway.Functional repair of p53 mutation in colorectal cancer cells using trans-splicing.Subchronic oral toxicity and metabolite profiling of the p53 stabilizing agent, CP-31398, in rats and dogsFrom keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma.Translational approaches targeting the p53 pathway for anti-cancer therapy.Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen.Targeting mutant p53 shows promise for sunscreens and skin cancerCrude Extracts, Flavokawain B and Alpinetin Compounds from the Rhizome of Alpinia mutica Induce Cell Death via UCK2 Enzyme Inhibition and in Turn Reduce 18S rRNA Biosynthesis in HT-29 Cells.TP53 modulating agent, CP-31398 enhances antitumor effects of ODC inhibitor in mouse model of urinary bladder transitional cell carcinoma.Combined inhibition of p38 and Akt signaling pathways abrogates cyclosporine A-mediated pathogenesis of aggressive skin SCCsMolecular basis for the tissue specificity of β-catenin oncogenesis.Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo.Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ miceFisetin inhibits growth, induces G₂ /M arrest and apoptosis of human epidermoid carcinoma A431 cells: role of mitochondrial membrane potential disruption and consequent caspases activation.p53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII-SV40T mice.The antiproliferative function of violacein-like purple violet pigment (PVP) from an Antarctic Janthinobacterium sp. Ant5-2 in UV-induced 2237 fibrosarcoma.Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice.Pharmacological activation of p53 in cancer cellsNitric oxide-releasing sulindac is a novel skin cancer chemopreventive agent for UVB-induced photocarcinogenesis.Targeting the p53 pathway.Quercetin induces mitochondrial mediated apoptosis and protective autophagy in human glioblastoma U373MG cellsCytoplasmic functions of the tumour suppressor p53.Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats.Targeting cancer stem cells with p53 modulators.Hair follicle disruption facilitates pathogenesis to UVB-induced cutaneous inflammation and basal cell carcinoma development in Ptch(+/-) mice.Resuscitating wild-type p53 expression by disrupting ceramide glycosylation: a novel approach to target mutant p53 tumors.
P2860
Q21562186-00167985-BC27-47D7-85B1-BE77C828F04DQ26770856-FB651701-C3A0-4B84-B6AA-827FB1B7CB6EQ27000754-12CD5367-5F8F-4679-A2E2-F8F120A06AC1Q27651295-7A841BC7-E4DA-4970-ACBD-2312BB26BAFFQ33655329-D70BDEE9-8341-4EBA-A5C4-CD2CA0573F7BQ33755827-92F31660-75CD-4351-847C-2EC79564F51EQ33989650-06F2DF1C-3CFF-41E5-83AF-046AAAAAFE23Q34069279-C8B8C819-174A-4EEF-94D2-23E336B5B9A1Q34575966-4474214E-D3BF-4CD9-8DA9-55E1A23F5893Q34621019-A47211E5-12C9-4630-A637-D6C7BF8ED689Q34687279-943EB7E1-D6A8-4392-BD79-E1C0D75DBA71Q34713840-C411C232-A121-4367-ADAC-20FFA87C86CBQ34984571-B0C387B1-0B27-467C-8209-E0C6648FF7D3Q34997018-9D7B3274-1F00-436D-B5FC-79BDF7F45611Q35032846-922ABBF5-C3ED-40C7-8ED7-1F954F6B5655Q35273347-BDE26B8B-4E11-4752-A004-8FC881438A46Q35370602-1119CC7D-4AD9-4F43-A873-A33304C7132AQ35698913-F0058CEF-A0CF-4A2E-951B-3F98A010ED0DQ35708113-1959063F-E87C-4386-8C40-3DAB11B32A35Q36032244-F0EAA733-8E88-4395-963B-AB7C6493547CQ36173619-89E1807C-361B-4D77-BAC4-FBBF4B611DDCQ36254067-77B4CE0E-3F9E-4CE2-88B3-C709612FB376Q36309384-83F90DBC-8BF8-4F45-9DDF-7D5EDE1297ECQ36334062-CFBF7100-842C-4104-9A8F-1F8962CBF4FCQ36501328-F6EB14FD-9A69-477B-B114-52849812AA4BQ36820882-1AE6725B-F4DF-44B4-9158-93459E10B689Q37002735-6689E4F2-8F05-48FD-9640-9F6A70CEE420Q37051658-065011F0-457E-4B20-800D-EE2A55558AC1Q37061038-EB66E576-F66C-439F-B901-9A52A46BA0D3Q37141369-35B8B4D6-DD29-45D9-A300-E3C4EDAE14D9Q37162374-66A7969C-4FFB-4817-B590-6D73EA3EA026Q37191174-EF3C3F1A-AB4C-4FC5-9B0E-DD24DDE4756DQ37191199-6FB200CF-E44B-45DA-AF3E-7424D63E6A90Q37260683-163A9C23-7558-4BD5-BB0E-8B6F5B0B3AFBQ37393077-4CB8C177-4BBF-4AAA-92A5-E1D8F88306E3Q37466228-86F8A5A2-6EDF-4062-B340-9F4814DD68F6Q37473855-32E6F654-1A18-4FF5-8D25-E47E0149F484Q37564349-DFD106DC-206D-4670-B7BD-1F57A0E02302Q37734905-724D9FB8-A7AD-431F-A824-B1FA03193894Q37942529-5174BBFD-A69B-4DC4-9F9A-C177738EB879
P2860
CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
CP-31398 restores mutant p53 t ...... d skin carcinogenesis in mice.
@ast
CP-31398 restores mutant p53 t ...... d skin carcinogenesis in mice.
@en
type
label
CP-31398 restores mutant p53 t ...... d skin carcinogenesis in mice.
@ast
CP-31398 restores mutant p53 t ...... d skin carcinogenesis in mice.
@en
prefLabel
CP-31398 restores mutant p53 t ...... d skin carcinogenesis in mice.
@ast
CP-31398 restores mutant p53 t ...... d skin carcinogenesis in mice.
@en
P2093
P2860
P356
P1476
CP-31398 restores mutant p53 t ...... d skin carcinogenesis in mice.
@en
P2093
Arianna L Kim
David R Bickers
Levy Kopelovich
Mohammad Athar
Xiuwei Tang
P2860
P304
P356
10.1172/JCI32481
P407
P577
2007-12-01T00:00:00Z